

Optum® - ScriptSwitch™ Prescribing

Optum® ScriptSwitch™ Prescribing Clinical Decision Support – v7.02

INPS Vision Practice User Guide

Optum Customer Service

Support: 024 7621 4700

Email: support@scriptswitch.com



Optum Health Solutions (UK) Ltd
5 Merchant Square, Paddington,
London,
United Kingdom, W2 1AS

ScriptSwitch is a Class 1 Medical Device
(EU MDD 93/42/EEC) (UK MDR 2002)

Optum Health Solutions (UK) Ltd
5 Merchant Square, Paddington,
London, United Kingdom, W2 1AS

Version: 2.1



Optum®

The rights of Optum® to be identified as authors of this Work have been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher.

The information contained in this publication is correct at time of going to press and is subject to change without notice.

Optum® is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners.

About Optum®

Optum® is a leading health services and innovation company with more than 165,000 people worldwide, dedicated to helping make the health system work better for everyone. Optum has been involved in the UK healthcare arena since 2002. Together we combine clinical expertise, world-class analytics and technology, and practical experience working with the NHS and internationally. We create and deliver distinctive products and services helping clinicians deliver high quality, cost-effective healthcare and improve the lives and wellbeing of patients.

Optum Health Solutions (UK) work in close collaboration with all health care systems, including Primary Care, Clinical Commissioning Groups, Integrated Care Systems, Health Boards, NHS England, and NHS Improvement. Everything we do is about creating and using actionable insight to help make the health and care system work better for everyone. We do this by focusing on three strategic pillars including Medicines Optimisation, Population Health Management and Genomics. To learn more about Optum UK and its products and services visit www.optum.co.uk.

.

DISCLAIMER

ScriptSwitch Prescribing is intended for use by healthcare professionals and is provided on the basis that the healthcare professionals retain full and sole responsibility for deciding what treatment to prescribe or dispense for any particular patient and whether particular recommendations are appropriate for a given patient. Without limiting the generality of the foregoing, it is at the discretion of the healthcare professional as to whether or not to use or accept any Recommendation included in the Recommendations Profile and to confirm that the quantity, dose, instructions, and duration ScriptSwitch Prescribing fields are completed and appropriate for the applicable patient. Please note that the quantity may have been changed to the closest available pack size.

For purposes of this disclaimer only, the "Recommendation" is defined as recommendations, as drafted or approved (or otherwise imported into ScriptSwitch Prescribing) by customers of ScriptSwitch Prescribing software, for substitutions from one drug to one or more others or recommendations as a message associated with one drug and "Recommendations Profile" is defined as the distributed database containing prescribing advice in the form of Recommendations and then compiled into electronically accessible Recommendations using the ScriptSwitch Prescribing software.

While all cost savings, medicinal product prices, or other data authored or otherwise generated or imported by Optum Health Solutions (UK) Limited "OHS" (all or some of which may represent estimations) presented in ScriptSwitch Prescribing (collectively, the "Information") are believed to be complete and accurate, OHS does not warrant or guarantee the completeness, correctness, accuracy, or timeliness of any of the Information. Further, Optum does not warrant or guarantee the completeness, clinical appropriateness or safety, correctness, accuracy, or timeliness of the Recommendations/ Recommendation Profile. Without limiting the generality of the foregoing, Optum does not warrant or guarantee the completeness, clinical appropriateness or safety, correctness, accuracy, or timeliness of the appearance or lack thereof of the Recommendations/Recommendation Profile for any particular patient.

In no event shall OHS be liable for any damages whatsoever arising out of the content of or use, reliance on, inability to use, or the resulting use of (i) the Information; (ii) the Recommendations/ the Recommendation Profile or (iii) the underlying drug data or drug updates, whether based on warranty, contract, tort, or any other legal theory. Any and all liability for the content or any omissions from ScriptSwitch Prescribing, including any inaccuracies, errors, or misstatements is expressly disclaimed. All other damages (where direct or indirect, special, incidental, consequential, or punitive) are hereby excluded to the fullest extent allowed by law. OHS may make changes to the Information at any time without notice. The Information may be out of date and OHS makes no commitment to update the Information. The Information is of a general nature and is not intended to address the circumstances of any particular individual or entity.

ScriptSwitch Prescribing safety alerts (the "Alerts") are intended for use by healthcare professionals and is provided on the basis that the healthcare professionals retain full and sole responsibility for deciding (i) what clinical care and/or treatment (including, but not limited to, prescribing drugs) to order, prescribe, dispense, or otherwise recommend for any particular patient; and (ii) whether any particular Alert is or is not appropriate for a given patient. Without limiting the generality of the foregoing, it is at the discretion of the healthcare professional as to whether or not to take any action based on any particular Alert. For the purposes of this disclaimer, the Alert is defined as ScriptSwitch Prescribing integrated alerts that utilise clinical rules/algorithms that will identify patients where a potential action is needed relating to medications or to manage specific conditions, in order to reduce the likelihood of negative health outcomes and reduce healthcare costs.

*OHS does not draft the clinical rules involved in determining the content of or when Alerts appear or do not appear in general or for any particular patient. Further, OHS does not warrant or guarantee the completeness, correctness accuracy, or timeliness of the appearance or lack thereof of any of the Alerts in general or for any particular patient. **Without limiting the generality of the foregoing, OHS advises the health care professional that Alerts do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug (or other) allergies; in all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug (and other) allergies.***

In no event shall OHS be liable for any damages whatsoever arising out of the content of or use, reliance on, inability to use, or the resulting use of the Alerts whether based on warranty, contract, tort, or any other legal theory. Any and all liability for the content or any omissions from Alerts, including any inaccuracies, errors, or misstatements is expressly disclaimed by OHS. All other damages (where direct or indirect, special, incidental, consequential, or punitive) are hereby excluded to the fullest extent allowed by law.

Any examples, suggestions, Recommendation Profiles, pharmaceutical products or appliances presented are solely to help customers understand the flexibility of the product, its aims and how it can be used. OHS gives no warranty that such indications are accurate, up-to-date, effective, complete, or suitable for the customer's purposes or that any of the pharmaceutical products or appliances referred to are or will be generally available in the market; are free of limitations in their purchase or use in the customer's jurisdiction; or that those not referred to are inappropriate.

The customer acknowledges that use of the ScriptSwitch Prescribing product and services is based solely on its own calculations; the preferences and content of any Recommendation Profile developed by it is and remains its sole responsibility; it is not entitled to rely on the specific details of ScriptSwitch Prescribing's samples or other explanatory information and; all liability of ScriptSwitch Prescribing however arising in relation to such information is expressly excluded to the fullest extent permitted by law.

Document History

| History | | | |
|---------|------------|--------|--|
| Version | Date | Author | Changes |
| 1.0 | 23/12/2021 | VH | Launch of ScriptSwitch Prescribing |
| 1.1 | 20/06/2022 | VH | Addition of actionable safety alerts |
| 2.0 | 30/03/2023 | VH | New pop-up design and introduction of Safety Interventions on the pop up |
| 2.1 | 19/06/23 | VH | Update to reflect software version deployed |

Table of Contents

| | |
|---|----|
| Who are Optum Health Solutions UK? | 7 |
| Software Version | 7 |
| Customer Service | 7 |
| Support on prescribing recommendations | 7 |
| What is ScriptSwitch™ Prescribing - Clinical Decision Support?..... | 8 |
| ScriptSwitch Prescribing as a Medical Device | 8 |
| ScriptSwitch Prescribing Intended Purpose | 8 |
| Intended Use – how to use the device | 8 |
| Intended patient population | 9 |
| Intended user environment / intended user | 9 |
| Principles of operation of the device and its mode of action | 9 |
| Claims..... | 10 |
| Supporting local prescribing choices in Primary Care | 11 |
| Prescribing Decision Support..... | 12 |
| KEY BENEFITS - For Prescribers | 13 |
| ScriptSwitch™ Prescribing and Clinical Systems | 14 |
| The Recommendation Profile | 15 |
| How does ScriptSwitch Prescribing Work? | 16 |
| ScriptSwitch Prescribing Offer Screen | 16 |
| Costings on the Pop-Up | 18 |
| Information Messages | 19 |
| Multiple Alternative Products | 20 |
| Formulation Mismatches and ScriptSwitch | 21 |
| Quantity Restricted Switches | 22 |
| Providing Feedback on the Recommendation | 23 |
| Capping of repeats on GP Pop-up | 24 |
| Patient Record Integration & Withholding | 25 |
| Optum Client Manager | 25 |
| ScriptSwitch Safety Alerts | 26 |
| What are the Safety Alerts? | 27 |
| How ScriptSwitch Safety Alerts work | 29 |
| Actioning a Safety Alert | 30 |
| Update Review Reasons and Save & Close Alerts..... | 30 |
| Hiding a Single Alert | 32 |



- Targeted Safety Alerts on the Prescribing Pop Up 33
- Prescriber Experience 34
- Data Processing..... 34
- INPS VISION & ScriptSwitch Prescribing..... 35
 - Trigger Points..... 35
 - What is Patient Record Integration (PRI)? 35
 - ScriptSwitch Prescribing Installation 36
 - To activate the site for ScriptSwitch Prescribing the following steps take place: 36
 - User Activation 37
- Frequently Asked Questions 40
- On-going Support 41
 - How to contact Customer Services:..... 41
 - Technical Issues 41
 - Software Updates..... 42



Who are Optum Health Solutions UK?

Optum Health Solutions UK is part of UnitedHealth Group - one of the most successful global health and well-being companies. Since 2002, we have been working in close partnership with all levels of the NHS, including Primary Care Trusts, Strategic Health Authorities, GP Commissioning Groups, and the Department of Health.

We draw upon our global expertise and experience to support the NHS in delivering high quality and cost-effective health care and improve the lives and well-being of patients. We combine leading edge information technology, analytics, consulting, and health management solutions to drive improvements in health outcomes using the most clinically and cost-effective evidence base.

We provide support in a range of areas including:

- Data management and analytics.
- Disease prevention and utilisation management capabilities.
- Medicines Optimisation, and Case and Condition Management.
- Risk stratification, profiling, and financial risk-pooling

ScriptSwitch™ Prescribing is a solution owned by Optum Health Solutions UK Limited (“OHS”) and is contracted into 36 Primary Care Organisations covering approximately 3,000 practices (March 2023).

Software Version

Version 7.02 Released: June 2023

Customer Service

Our Customer Services team is available as follows:

Time: Monday to Friday 8.00am – 6.00pm

Tel No: 02476 214 700

Email: support@scriptswitch.com

Support on prescribing recommendations

Please contact your local Medicines Optimisation Prescribing Team

ScriptSwitch™ is a registered trademark of Optum Health Solutions (UK) Ltd

What is ScriptSwitch™ Prescribing - Clinical Decision Support?

ScriptSwitch Prescribing – Clinical Decision Support is one of the UK’s leading prescribing decision support solutions for healthcare professionals within the primary care sector, and is the only technology tool, compatible with all the major clinical systems, that releases savings at the point of prescribing.

With so many considerations and pressures placed upon the prescriber’s workload, ScriptSwitch Prescribing delivers both national guidelines, local initiatives, and formulary choices instantly, without the need to remember or locate the numerous sources of such information.

ScriptSwitch Prescribing as a Medical Device

ScriptSwitch Prescribing - Clinical Decision Support – clinical management support software, hereinafter referred to as “ScriptSwitch Prescribing”, was registered as a Class 1 Medical Device with the MHRA under UK Medical Device Regulations 2002 (EU MDD 93/42/EEC) (UK MDR 2002) in December 2021.

ScriptSwitch Prescribing Intended Purpose

Intended Use – how to use the device

- ScriptSwitch Prescribing is software that supports prescribers in identifying potential medication safety issues.
- ScriptSwitch Prescribing does this by providing prescribers with information identified as a potential medication safety issue for a prescriber to review.
- ScriptSwitch Prescribing is software that supports prescribers when they have already made a working diagnosis and have already made a prescribing decision to select a lower cost, more cost effective or potentially safer alternative prescription
- ScriptSwitch Prescribing does this by providing information to support prescribing decisions once a prescription has been entered into the Electronic Medical Record by a prescriber. It does not support diagnosis. It does not support treatment and disease management decisions.
- A prescriber can freely choose to accept this advice and amend their prescription choice or not.
- ScriptSwitch Prescribing does this via a pop-up that appears in the prescribing workflow of the Electronic Medical Record after a prescriber has made a working diagnosis and a prescribing decision has been made by the prescriber.
- ScriptSwitch Prescribing is not intended to address any specific disease or condition. It is intended to offer support on prescribing decisions across all prescription types.
- ScriptSwitch Prescribing does not diagnose, investigate, prevent, monitor, predict, provide a prognosis, or alleviate disease or compensate for an injury or disability.

Intended patient population

- ScriptSwitch Prescribing is intended to be used across the whole general patient population of a primary care GP practice (i.e., the whole practice patient list).
- It is not specific to any age group, demographic, or condition. It is not intended to be used in a specific cohort or disease.
- It is not intended for patients in secondary care hospital use. It will not work in the secondary care environment.

Intended user environment / intended user

- ScriptSwitch Prescribing is intended to be used by medical or non-medical prescribers only. It is not intended to be used by lay people or administrative staff.
- ScriptSwitch Prescribing is specifically aimed at medical and non-medical qualified prescribers in primary care in the context of their day-to-day routine prescribing within primary care.
- ScriptSwitch Prescribing is intended to be used in General Practice by qualified medical or non-medical prescribers in the context of their day-to-day routine prescribing within primary care.

Principles of operation of the device and its mode of action

ScriptSwitch Prescribing is a computerised prescribing decision support tool that offers:

- a suggested alternative prescription after an initial prescription decision has been made. The prescriber can review information on a possible alternative formulation to that which they have selected in a pop-up. The prescriber is clinically accountable for the decision as to whether to accept or decline the suggestion with a single click of a button on the pop-up. The prescriber can review the details of the suggestion on the pop-up to decide whether to accept the alternative based on their clinical decision and their knowledge of the patient. There is no requirement that prescribers accept the alternative.
- A pop-up containing information about a potential medication safety issue. This presents upon opening the patient's electronic medical record if ScriptSwitch Prescribing has identified a potential medication safety issue. The end-user may choose to take no action or ignore the pop-up. There is no requirement for the end-user to take an action.
- The prescribing recommendations offered to prescribers are authored and selected by qualified and authorised staff, such as senior pharmacists and senior medical prescribers of the buyer of the ScriptSwitch Prescribing software and are typically NHS payer organisations including Clinical Commissioning Groups and Health Boards.
- Upon request Optum® can also author and provide prescribing recommendations but the buyer is accountable and responsible for acceptance and deployment of the recommendations to the primary care prescribers

- ScriptSwitch Prescribing is presented after a working diagnosis has been made by a prescriber and a prescribing decision has been made by a prescriber. The ScriptSwitch Prescribing will present based upon the prescription details entered by the prescriber into the Electronic Medical Record prescribing module. If these details match the parameters of a recommendation for an alternative prescription as decided by the buyer of ScriptSwitch Prescribing, this will present and display information for the prescriber to review. The presentation of the is facilitated through an Application Partner Interface between ScriptSwitch Prescribing and the Electronic Medical Record (EMR). ScriptSwitch Prescribing does not perform any manipulation of the EMR data.

Claims

- Increases cost effectiveness of prescribing and lowers prescribing costs by offering suggestions for more cost effective or lower cost prescriptions.
- Can increase formulary compliance by recommending more cost effective or lower cost prescriptions that are on the buyer's formulary.
- Can improve patient adherence to their prescribed regime by supporting prescribers to select more appropriate prescription choices.
- Offers suggestion that may include safer prescribing choices on the ScriptSwitch Prescribing for prescribers to review.

Supporting local prescribing choices in Primary Care

ScriptSwitch Prescribing is a proven, clinically led solution that supports prescribing decisions so it's right for the patient, first time.

- With patient record integration, it evaluates the medical record before offering switches
- Integrated with evidenced-based clinical rules addressing safety, dose and waste
- Surfacing appropriate targeted messages, enabling GPs and prescribers to spend more time with patients

The tool encompasses three integrated components to continuously improve the effectiveness, safety and value of prescribing. We provide simple, easy-to-action recommendations to prescribers*.



Simplicity: Presents a clear, simple user interface with one-click action, combined with simplified dashboards that provide real-time data to easily track profile performance across every GP Practice




Safety: Uses targeted safety alerts to reduce the risk of patient harm, powered by complex clinical rules that alert the prescriber in a simple message when a patient record is opened




Savings: Helps systems to meet financial and sustainability goals tackling price and volume, the only way to truly lower prescribing costs and deliver additional savings

Prescribing Decision Support

Providing detailed, locally authored, drug switch recommendations, dosage optimisation information and patient safety information messages right at the point of prescribing, ScriptSwitch Prescribing can aid the prescriber's decision with a simple no-nonsense information screen that appears automatically and then requires just one click to accept or decline the recommendation.



ScriptSwitch Prescribing Decision Support

| | | |
|--|---|---|
| <p>Original</p> <p>Losec 10mg gastro-resistant capsules (28 capsule)</p> <p>One To Be Taken Each Day</p> <p>Est. Cost : £11.16</p> |  | <p>Replacement</p> <p>Omeprazole 10mg gastro-resistant capsules (28 capsule)</p> <p>One To Be Taken Each Day</p> <p>Est. Cost : £0.87</p> |
|--|---|---|

Cost Saving : **£10.29**

[Accept Replacement >](#)

[↔ Switch](#)

Prescribing generically is more cost-effective.

[< Back](#)
[Feedback](#)
[Continue with Original](#)

Optum

The health care professional is solely responsible for verifying the appropriateness of the Recommendation for the patient. Please check quantity, dose, instructions and duration fields are all completed and are appropriate for the patient; please also note savings shown are an estimate. The quantity may have been changed to the closest available pack size. ScriptSwitch will only populate drug, dose and quantity fields following acceptance of a recommendation. It is at the discretion of the health care professional to complete any and all other fields as appropriate. Further without limiting the generality of the foregoing, Optum Health Solutions (UK) advises the health care professional that Recommendations do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug (or other) allergies. In all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug (and other) allergies. The aforementioned is subject to the terms of the [Full Disclaimer](#).

The product is built from four core modules:

Profile contains recommendations which are generated by the customer prescribing support team (medicines optimisation teams) and loaded into a database known as the Recommendation Profile. ScriptSwitch Prescribing delivers this prescribing advice to clinicians at the point at which they use their own clinical system to generate a prescription.

ScriptSwitch Prescribing Pop-Up activates if, and only if, there is a recommendation available for the prescribed medication. ScriptSwitch Prescribing then provides the prescriber with the opportunity to choose whether to act on the advice; a decision is dependent upon the actual circumstances involved.

ScriptSwitch Safety Alerts pop-up supports prescribers to efficiently manage patient risk and reduce the likelihood of a medication related hospital admission

Analytics: Analysis of the data collected in Optum Intelligence and Data Analytics provides the prescribing support team and GP practices with a mechanism to update the Recommendation Profile and thereby continuously improve the targeting, and the nature, of the support offered.

KEY BENEFITS - For Prescribers

ScriptSwitch Prescribing delivers significant benefits for prescribers in Primary Care Organisations by improving medicines optimisation services. Listed below are some of the main areas where ScriptSwitch Prescribing can impact.

| | |
|--|---|
| Facilitating the management and implementation of prescribing information at practice level | <p>Prescribers are inundated with prescribing information</p> <p>and implementing this in practice can be time consuming. ScriptSwitch Prescribing brings clear, simple and</p> <p>concise clinical and financial information closer to the point of decision around drug selection. Changes can be implemented easily with a single “mouse-click”.</p> |
| Improved performance in GMS contract, prescribing indicators, and prescribing incentive schemes | <p>Support to prescribers can optimise performance in measures that monitor prescribing.</p> |
| Implementation of NICE and other guidelines | <p>Supports targeted intended medicines usage as described in local and national guidelines. Information message reports can monitor dissemination of guidance and demonstrate a commitment to evidence-based practice.</p> |
| Sustainability | <p>Presents constant reminders on optimal drug selection to prescribers</p> |
| Spread of better practice | <p>ScriptSwitch Prescribing can provide the means to inform, interact</p> <p>with, and positively influence all medical and non medical prescribers with access to a compatible Clinical system. This also includes those who are not regular members of the care team e.g., GP locums.</p> |
| Increased formulary adherence | <p>Helps to reduce variation in prescribing, particularly in larger practices with greater numbers of prescribers.</p> |

| | |
|---|---|
| Improved safety around the use of high-risk medicines | ScriptSwitch Prescribing can be used to highlight to prescribers' drugs that carry risks. Messages can disseminate local learning around prescribing related near misses/critical incidents. This can reduce the risk of error. |
| Reduced prescribing of high-cost drugs that should be prescribed by secondary care | Information messages can raise awareness of and reinforce local guidelines on red and amber drugs |
| Raised awareness of shared care agreements and clinical responsibility | Information messages can clarify any shared care arrangements and reassure the prescriber when making decisions, about clinical and prescribing responsibility |

ScriptSwitch™ Prescribing and Clinical Systems

ScriptSwitch Prescribing currently works with the following clinical systems:

- EMIS PCS - Scotland
- EMIS WEB
- INPS Vision
- INPS Vision Enterprise (AEROS)
- Cegedim Cloud
- TPP SystemOne

The ScriptSwitch Prescribing product will trigger at different points within each of the clinical systems above depending on the integration.

The Recommendation Profile

ScriptSwitch Prescribing provides your local Medicines Optimisation teams with access to an online tool to enable the development of a locally authored recommended drug profile. This drug profile can contain drug switches and safety warning messages, along with general prescribing advice.

The Recommendation Profile is developed, maintained, and deployed by your local Medicines Optimisation teams.

To receive the Recommendation Profile the ScriptSwitch Prescribing software must still be installed and active at the practice.

ScriptSwitch Prescribing pro-actively monitors the successful deployment of the Recommendation Profiles to ensure that the practices are working on the latest recommendations from the local Medicines Optimisation teams. Any sites who have not received the Recommendation Profile will be contacted by our Customer Services team to identify and resolve the issue.

The system is kept up to date with monthly updates from Dm+d and the BNF/BNFC.

How does ScriptSwitch Prescribing Work?

ScriptSwitch Prescribing Offer Screen

ScriptSwitch Prescribing is a tool that is integrated with the GP's Clinical System. A drug profile is maintained by the local Medicines Optimisation team and is delivered electronically to each prescriber's PC. The information within the recommendation profile is kept up to date by the local Medicines Optimisation team.

From within INPS Vision at the point of prescribing, if a product prescribed by the clinician has either a potential alternative drug or an information message a window will appear whilst prescribing as follows:

Sample Switch - simple switch

The screenshot displays the 'ScriptSwitch Prescribing Decision Support' interface. It compares an 'Original Product' (Losec 10mg gastro-resistant capsules, 28 capsules, £11.16) with a 'Replacement product and dosage' (Omeprazole 10mg gastro-resistant capsules, 28 capsules, £0.87). A 'Cost Saving' of £10.29 is highlighted. A 'Switch' button is present, with a justification message: 'Prescribing generically is more cost-effective.' At the bottom, there are 'Action Buttons' including '< Back', 'Feedback', 'Continue with Original', and an 'Accept Replacement >' button. The Optum logo is in the bottom right corner.

Original Product

Replacement product and dosage

Estimated cost benefit

Cost Saving : £10.29

Accept Replacement >

Switch

Justification message

States the reason for pop-up

Action Buttons

Optum





The health care professional is solely responsible for verifying the appropriateness of the Recommendation for the patient. Please check quantity, dose, instructions and duration fields are all completed and are appropriate for the patient; please also note savings shown are an estimate. The quantity may have been changed to the closest available pack size. ScriptSwitch will only populate drug, dose and quantity fields following acceptance of a recommendation. It is at the discretion of the health care professional to complete any and all other fields as appropriate. Further, without limiting the generality of the foregoing, Optum Health Solutions (UK) advises the health care professional that Recommendations do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug (or other) allergies; in all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug (and other) allergies. The aforementioned is subject to the terms of the [Full Disclaimer](#).

The screen displays a “**switch**” message box which needs to be actioned.

The screen may offer several alternative drug options which can be selected by using the mouse to highlight them. These may be based on:

- Alternative drug
- Same drug alternative dosage
- Alternative drug, alternative dosage

Following selection of the required option, the following actions are available:

| | |
|--|---|
| <p>Accept Replacement</p>  | <p>Selects the replacement product and populates the prescribing screen with the product, dosage and quantities.</p> <p>This can be edited in the clinical system as required</p> |
| <p>Back (Edit Original)</p>  | <p>Returns to the original prescribing window where the original product can be changed</p> |
| <p>Continue with Original</p>  | <p>Prescribes the original product</p> |
| <p>Feedback</p>  | <p>A free text box is provided to allow feedback on the displayed switch and content directly to the local Medicines Optimisation team. Please do not enter patient information</p> |

Costings on the Pop-Up

Your local Medicines Optimisation team may have taken the decision to suppress the cost of some recommendations and replace this with a reason for the recommendation.

These reasons may display as follows:

- Cost effective switch
- Local formulary supported switch
- Quality Clinical Switch
- Other message – free text is available to your local Medicines Optimisation team

The screenshot displays the 'ScriptSwitch Prescribing Decision Support' interface. It compares an 'Original' prescription of 'Dulcolax 10mg suppositories (12 suppository)' with a 'Replacement' of 'Bisacodyl 10mg suppositories (12 suppository)'. A message states 'Brand not available on NHS script'. A red arrow points from this message to a 'Switch' section below, which contains the text: 'Dulcolax suppositories is not prescribable on the NHS. Bisacodyl must be prescribed generically.' This text is highlighted with a light blue box and labeled 'Cost replaced with message'. At the bottom, there are buttons for '< Back', 'Feedback', and 'Continue with Original', along with the Optum logo and a disclaimer.

The following messages may also appear on the

- **Negative cost saving** – where the recommended replacement will generate a negative saving. It may be clinically appropriate. The Medicines Optimisation team can be notified by using the feedback button. The recommendation details will be automatically sent with your feedback
- **Unable to calculate cost saving** – this normally appears when there is a formulation mismatch e.g. Liquids to tablets.

Information Messages

The local Medicines Optimisation team may decide to implement information only messages within the profile. These will pop-up to provide additional prescribing support to the clinician and may include links to further evidence about the product being prescribed.

Sample Information Message

ScriptSwitch Prescribing Decision Support

Original
Glycopyrronium bromide 1mg tablets (30 tablet)
as directed
Est. Cost : **£262.81**

Continue with Original >

Information




lato luto lento defleo juvenus late gutter deleo filius equinus erratum enim equinus consanguineus gutter is aegroto lacer ile ibidem illum letalis discedo longus filia illi donec illum labiae latenter eatenus fortasse is is faux laetitia longe enim effluo effluo fatigo illo fatigo exsanguis iamdiu lactatio fortis efficaciter libricus momentum id faux iaceo iam ictus eventus ilico loco ilico deleo ille immunda effingo gelu decurro labiae frater fuga lego ictus ivi illa ibidem fidens edico exsanguis gusto despero

< Back

Feedback

Optum

The health care professional is solely responsible for verifying the appropriateness of the Recommendation for the patient. Please check quantity, dose, instructions and duration fields are all completed and are appropriate for the patient; please also note savings shown are an estimate. The quantity may have been changed to the closest available pack size. ScriptSwitch will only populate drug, dose and quantity fields following acceptance of a recommendation. It is at the discretion of the health care professional to complete any and all other fields as appropriate. Further, without limiting the generality of the foregoing, Optum Health Solutions (UK) advises the health care professional that Recommendations do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug (or other) allergies; in all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug (and other) allergies. The aforementioned is subject to the terms of the [Full Disclaimer](#).

| | |
|--|--|
| Continue with Original  | Selecting this option will continue with the original product and return to the prescribing screen to complete the script |
| Back  | Returns to the prescribing screen to allow the original drug to be edited |
| Feedback  | A free text box will appear which allows the clinician to provide feedback on the information message to the local Medicines Optimisation Team. Please do not provide patient information. |

Multiple Alternative Products

The local Medicines Optimisation teams may recommend more than one replacement product. The preferred replacement will populate the pop-up, but the other products will be available for selection below, by clicking the radio button to select.

ScriptSwitch Prescribing Decision Support

Original

Durogesic DTrans 100micrograms/hour transdermal patches (10 patch)

APPLY ONE EVERY 3 DAYS

Est. Cost : **£115.72 for 1 repeat**

Replacement

Fencino 100micrograms/hour transdermal patches (10 patch)

APPLY ONE EVERY 3 DAYS

Est. Cost : **£77.76 for 1 repeat**

Cost Saving : **£37.96 for 1 repeat**
12 Repeat(s) Prescribed

Accept Replacement >

Select alternatives with Radio button

Switch

1st line formulary choice

Fencino transdermal patches are a more cost effective brand of FENTANYL PATCH and the recommended first line brand choice in the [local formulary](#).

Please note: Fencino is **contraindicated** in patients allergic to peanuts or soya.

Information

MHRA Safety information:

1. **DRIVING:** Advise patient it is against the law to drive if driving ability is impaired.

All available replacements

| | Est. Cost |
|---|----------------------------|
| <input checked="" type="radio"/> Fencino 100micrograms/hour transdermal patches (10 patch) | £77.76 for 1 repeat |
| <input type="radio"/> Matrifen 100micrograms/hour transdermal patches (10 patch) | £69.18 for 1 repeat |

Scroll bar for full Justification text

Optum

[Full Disclaimer >](#)

This screen shot also show additional justification text and information message that can be viewed relating to the replacement product. The scroll bar can be used to view additional text.

Formulation Mismatches and ScriptSwitch

The Medicines Optimisation team may recommend a switch of product between two products which have inequivalent dose units (e.g., liquid to tablet). In this instance the prescriber will need to confirm the dosage and quantity and click the **Calculate button**, prior to accepting the replacement.

This will ensure that:

- accurate costs and savings can be seen before deciding on the switch
- the replacement product will always have an appropriate dose and quantity
- accurate financial savings estimations captured in ScriptSwitch Prescribing reporting

The frequency of these types of recommendations is low and the ScriptSwitch Prescribing pop-up will look and behave slightly differently:

ScriptSwitch Prescribing Decision Support

Original
Sandimmun 100mg/ml oral solution (1 x 50 ml)
 1 OD
 Est. Cost : **£164.72**

Replacement
Sandimmun 50mg capsules (50 capsule)

Replacement Information Required

Quantity capsule Dosage

Calculate Est. Cost : TBC

Calculate first to see cost savings **Accept Replacement >**

Switch
 The dm+d is a dictionary of descriptions and codes which represent medicines and devices in use across the NHS.
 The dm+d contains a huge variety of information, including:

- whether a product will be reimbursed by us, if submitted for reimbursement by a dispensing contractor
- the indicative price of each pack of a product (where a price is maintained by us)
- current and discontinued products and marks

< Back **Feedback** **Continue with Original**

Optum

Replacement Information Required

Unit(s) (capsule) Dose(s) Duration

Per Dose Per Day Day(s)

Done

Quantity Restricted Switches

This ScriptSwitch feature addresses volume and enables Medicine Optimisation Teams to deploy switches that offer prescribers a suggested limit to the quantity of the product being prescribed.

The benefits of this feature include:

- Improve patient safety through recommendations for safer quantities of controlled drugs and hypnotics
- Support antibiotic stewardship through targeted messages on course length
- Reduce quantities and waste of appliances including wound care, catheters, stoma and tracheostomy and laryngectomy

The screenshot displays the 'ScriptSwitch Prescribing Decision Support' interface. It compares an 'Original' prescription of 'Ozempic 1mg/0.74ml solution for injection 3ml pre-filled pens (6 x pre-filled disposable injection)' with an 'Est. Cost : £439.50' to a 'Replacement' of 'Ozempic 1mg/0.74ml solution for injection 3ml pre-filled pens (2 x pre-filled disposable injection)' with an 'Est. Cost : £146.50'. A red box highlights the text '(Quantity Restricted Switch)' in the replacement section, with a red arrow pointing to it from a text box on the right. The 'Cost Saving : £293.00' is shown, along with an 'Accept Replacement >' button. Below this, a 'Switch' section explains the 'Quantity Limit Switch' and provides details about Ozempic. At the bottom, there are buttons for '< Back', 'Feedback', and 'Continue with Original', along with a disclaimer and the Optum logo.

ScriptSwitch Prescribing Decision Support

Original
Ozempic 1mg/0.74ml solution for injection 3ml pre-filled pens (6 x pre-filled disposable injection)
 USE AS DIRECTED
 Est. Cost : **£439.50**

Replacement
Ozempic 1mg/0.74ml solution for injection 3ml pre-filled pens (2 x pre-filled disposable injection)
 USE AS DIRECTED
 (Quantity Restricted Switch)
 Est. Cost : **£146.50**

Cost Saving : **£293.00**

Accept Replacement >

Switch

- **Quantity Limit Switch** - This recommendation is to reduce/limit the prescribed quantity of the original product.
- The original product, formulation, strength and dose are unchanged for the replacement.
- Ozempic is a glucagon-like peptide-1 (GLP-1 agonist) used to treat diabetes. It comes as a pre-filled pen to be used once a day. A single pen will last for one month.
- **The Quantity Limit is for a 56 day supply**

< Back **Feedback** **Continue with Original**

The health care professional is solely responsible for verifying the appropriateness of the Recommendation for the patient. Please check quantity, dose, instructions and duration fields are all completed and are appropriate for the patient; please also note savings shown are an estimate. The quantity may have been changed to the closest available pack size. ScriptSwitch will only populate drug, dose and quantity fields following acceptance of a recommendation. It is at the discretion of the health care professional to complete any and all other fields as appropriate. Further, without limiting the generality of the foregoing, Optum Health Solutions (UK) advises the health care professional that Recommendations do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug (or other) allergies; in all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug (and other) allergies. The aforementioned is subject to the terms of the [Full Disclaimer >](#)

Optum

Indicates recommendation is a quantity restricted switch and may not be a change of product

- When a prescriber prescribes a product that results in a replacement quantity that would exceed the recommended maximum quantity limit, the quantity of the replacement will be restricted on the pop-up.
- The pop-up will clearly display that this is a Quantity Restricted Switch.
- Click **Accept Replacement** to accept the *restricted quantity*.

Providing Feedback on the Recommendation

The feedback option can be used to provide information to the profile author relating to the recommendation. E.g., product out of stock, or description needs more information.

Sample Feedback Screen (relates to switch on page 14)

ScriptSwitch Prescribing Decision Support

Original
Dulcolax 10mg suppositories (12 suppository)
One To Be Inserted Each Morning

Replacement
Bisacodyl 10mg suppositories (12 suppository)
One To Be Inserted Each Morning

Brand not available

Switch
Dulcolax suppositories is not prescribable on the

< Back

Feedback

Continue

The health care professional is solely responsible for verifying the accuracy of the information for the patient; please also note savings shown are an estimate. This is a recommendation. It is at the discretion of the health care professional that recommendations do not incorporate (directly or indirectly) to drug (or other) allergies in all cases the user is subject to the terms of the [Full Disclaimer](#).

ScriptSwitch Prescribing Decision Support

Feedback - select which recommendation(s) you would like to leave feedback on

Original
Durogesic DTrans 100micrograms/hour transdermal patches (10 patch)
APPLY ONE EVERY 3 DAYS
Est. Cost : **£115.72 for 1 repeat**

Replacement
Fencino 100micrograms/hour transdermal patches (10 patch)
APPLY ONE EVERY 3 DAYS
Est. Cost : **£77.76 for 1 repeat**

Switch
1st line formulary choice
Fencino transdermal patches are a more cost effective brand of FENTANYL PATCH and the recommended first line brand choice in the [local formulary](#).
Please note: Fencino is **contraindicated** in patients allergic to peanuts or soya.

Information

MHRA Safety information:

- DRIVING:** Advise patient it is against the law to drive if driving ability is impaired by Fentanyl. Advise to not drive until it is known how the medicine affects them or if they feel drowsy. See [Drug Safety Update](#) for further information.
- SAFE DISPOSAL:** Advise patient to dispose of the used patch safely. Provide MHRA patient leaflet on the safe disposal. See [Drug Safety Update](#) for further

All available replacements

☒ **Fencino 100micrograms/hour transdermal patches (10 patch)**

Est. Cost
£77.76 for 1 repeat

☐ Matrifen 100micrograms/hour transdermal patches (10 patch)

Est. Cost
£69.18 for 1 repeat

Feedback for Fencino 100micrograms/hour transdermal patches

Enter feedback to your medicines management team. Do not include patient identifiable data (required field)

Cancel

Prescriber Name (optional)

Send

This feedback will be sent to your medicines management team

Optum

| | |
|--|---|
| Feedback | Feedback relating to the selected product can be entered. Please do not enter patient information |
| Prescriber <div>Prescriber Name(optional)</div> | Prescriber name can be entered - optional |
| Send <div>Send</div> | Clicking the Send delivers the message to your local Medicines Optimisation team, along with the details of the recommendation |
| Cancel <div>Cancel</div> | Returns to the original ScriptSwitch Prescribing recommendation/information message window - no feedback is recorded. |

Version: 2.1

2023 Optum Health Solutions (UK) Limited. All rights reserved. Confidential property of Optum®.
Do not distribute or reproduce without express permission from Optum®.

Page 23 of 42

Capping of repeats on GP Pop-up

When a prescriber submits a repeat prescription, the recommendation Pop-up the cost savings for the switch may present different savings.

Where a regular daily dosage can be identified the Pop-up displays “**per annum**” calculation of the cost saving,

When a regular daily dosage cannot be identified the cost saving for “**1 repeat**” will be displayed

The Pop-up will display the number of repeats entered by the prescriber in the clinical system

Fig.1 – Dosage parsed:

ScriptSwitch Prescribing Decision Support

Original

Durogesic DTrans 100micrograms/hour transdermal patches (10 patch)
 APPLY ONE EVERY 3 DAYS
 Est. Cost : **£115.72 for 1 repeat**

Replacement

Fencino 100micrograms/hour transdermal patches (10 patch)
 APPLY ONE EVERY 3 DAYS
 Est. Cost : **£77.76 for 1 repeat**

Cost Saving :

£37.96 for 1 repeat
 12 Repeat(s) Prescribed

Accept Replacement >

Switch

1st line formulary choice

Fencino transdermal patches are a more cost effective brand of FENTANYL PATCH and the recommended first line brand choice in the local formulary.

 Please note: Fencino is **contraindicated** in patients allergic to peanuts or soya.

Information

MHRA Safety information:

 1. **DRIVING:** Advise patient it is against the law to drive if driving ability is impaired.

All available replacements

| | Est. Cost |
|---|----------------------------|
| <input checked="" type="radio"/> Fencino 100micrograms/hour transdermal patches (10 patch) | £77.76 for 1 repeat |
| <input type="radio"/> Matrifen 100micrograms/hour transdermal patches (10 patch) | £69.18 for 1 repeat |

< Back

Feedback

Continue with Original

Optum

The health care professional is solely responsible for verifying the appropriateness of the Recommendation for the patient. Please check quantity, dose, instructions and duration fields are all completed and are appropriate for the patient; please also note savings shown are an estimate. The quantity may have been changed to the closest available pack size. ScriptSwitch will only populate drug, dose and quantity fields following acceptance of a recommendation. It is at the discretion of the health care professional to complete any and all other fields as appropriate. Further, without limiting the generality of the foregoing, Optum Health Solutions (UK) advises the health care professional that Recommendations do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug (or other) allergies; in all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug (and other) allergies. The aforementioned is subject to the terms of the [Full Disclaimer](#) >

Version: 2.1

Page 24 of 42

2023 Optum Health Solutions (UK) Limited. All rights reserved. Confidential property of Optum®.

Do not distribute or reproduce without express permission from Optum®.

Patient Record Integration & Withholding

ScriptSwitch Prescribing can be configured to use patient specific information to present recommendations based on patient demographics, medication history, lab results and diagnosis.

This may result in the following behaviour in relation to switch presentation:

- A switch may not be presented if the replacement product is unlicensed for the age and inappropriate for gender of the patient as defined by the BNF/BNFC
- If a specific switch has been rejected twice for the same patient by the same prescriber within the last 12 months, the recommendation will not be shown for the same patient, from the same clinician for another 12 months, i.e. it will be with-held

These features will be activated on completion of the appropriate data sharing agreements by your local Medicines Optimisation team. The activation process will occur on the ScriptSwitch Prescribing hosted database.


Optum Client Manager

This is a software component which is installed on all machines that use ScriptSwitch Prescribing.

Client Manager is used to process the patient record information when the patient record integration features are activated. It will hold the clinical system patient ID and pass this to the ScriptSwitch Prescribing software at the point of prescribing.

For Withholding, it will hold the prescriber ID and clinical system patient ID and if a recommendation is rejected, this information will be sent to the ScriptSwitch Prescribing system to be used when the patient next presents. This encrypted data will be held by Optum for 12 months in an encrypted database and will be automatically deleted after 12 months.

The ScriptSwitch Prescribing Client Manager will show the following icon in the system tray



ScriptSwitch Safety Alerts

Optum have introduced a safety alert solution that presents patient specific and evidence-based safety alerts to prescribers when the patient record **is opened**.

The ScriptSwitch Safety Alerts pop-up supports prescribers to efficiently manage patient risk and reduce the likelihood of a medication related hospital admission.

Alerts will introduce the PINCER indicators and provides an additional evidence base to support decision making and safe, quality prescribing.

For more information on PINCER indicators click [here](#).

The clinical rules are run against the patient data, in real time and a Safety Alert presented to the clinician in an easy to digest summary.

The summary enables the clinician to quickly assess risks relating to their patient and highlights changes to medications or required tests that can be discussed with the patient during the consultation.

The clinician can record any action taken against the Safety Alert and this will be aggregated at practice level and recorded within ScriptSwitch Analytics for review at overall ICB level.

Note: This service will be activated following instructions to Optum from your Medicines Optimisation teams

What are the Safety Alerts?

The ScriptSwitch Safety Alerts pop-up will initially utilise the 13 PINCER rules, as detailed below:

| RuleID | Type | Title | Rule |
|---------------|----------------------|---|--|
| A | Admissions Avoidance | Age 65+, on oral NSAID without gastroprotection | Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient aged ≥ 65 years |
| B | Admissions Avoidance | H/O peptic ulcer, on oral NSAID without gastroprotection | Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient with a history of peptic ulceration |
| C | Admissions Avoidance | H/O peptic ulcer, on OAC without gastroprotection | Prescription of an antiplatelet drug without co-prescription of an ulcer-healing drug, to a patient with a history of peptic ulceration |
| D | Admissions Avoidance | On OAC and oral NSAID | Prescription of warfarin or DOAC in combination with an oral NSAID |
| E | Admissions Avoidance | On OAC and antiplatelet without gastroprotection | Prescription of warfarin or DOAC and an antiplatelet drug in combination without co-prescription of an ulcer-healing drug. |
| F | Admissions Avoidance | On aspirin and antiplatelet without gastroprotection | Prescription of aspirin in combination with another antiplatelet drug without co-prescription of an ulcer-healing drug. |
| G | Admissions Avoidance | Asthma and non-selective BB | Prescription of a non-selective beta-blocker to a patient with a history of asthma |
| I | Admissions Avoidance | HF and oral NSAID | Prescription of an oral NSAID to a patient with heart failure |
| K | Admissions Avoidance | eGFR <45 and oral NSAID | Prescription of an oral NSAID to a patient with eGFR <45 |
| MO_P13 | Monitoring | Age 75+, on ACEI or loop, no renal function/electrolytes test | Patients aged 75 years and older who have been prescribed an angiotensin converting enzyme (ACE) inhibitor or a loop diuretic long term who have not had a computer-recorded check of their renal function or electrolytes in the previous 15 months |

| RuleID | Type | Title | Rule |
|--------|------------|--|--|
| MO_P15 | Monitoring | On methotrexate without recent FBC | Patients receiving methotrexate for at least three months who have not had a recorded full blood count (FBC) or liver function test (LFT) within the previous three months |
| MO_P17 | Monitoring | On lithium without recent lithium test | Patients receiving lithium for at least three months who have not had a recorded check of their lithium concentrations in the previous three months |
| MO_P18 | Monitoring | On amiodarone without recent TFT | Patients receiving amiodarone for at least six months who have not had a thyroid function test (TFT) within the previous six months |

Notes:

The PINCER rules will search the patient record and clinical system for the relevant tests and medication history, specifically:

- Last medication script date within the last 3 months
- Lab test results recorded in the clinical system, i.e., not in PDF format or in a separate lab results system or journal entries

How ScriptSwitch Safety Alerts work

When a patient record is opened the Safety Alert software will process the patient record – on the desktop – and run the clinical rules above.

If a rule generates a Safety Alert for a patient, a pop-up will be presented to the prescriber as follows:

ScriptSwitch Prescribing Safety Alerts

X

| | | | | |
|---------------------------------|--------------------------|------------------------------------|------------------------------|--------------------------------|
| First Name Cinderella | Last Name Ball | Date of Birth 15/03/1937 | NHS No: 9999999492 | Reference 9999999492 |
|---------------------------------|--------------------------|------------------------------------|------------------------------|--------------------------------|

| Level | Type | Details | Review Status | Review Reason |
|-------|----------------------|---|---------------|----------------------------------|
| RED | Admissions Avoidance | HF and oral NSAID Prescription of an oral NSAID to a patient with heart failure | ! | -Review Action- Hide Alert |
| RED | Admissions Avoidance | Age 65+, on oral NSAID without gastroprotection Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient aged ≥65 years | ✓ | Schedule consultation Hide Alert |

Cancel

Hide All and Close

Save and Close

The health care professional is solely responsible for verifying the appropriateness of the Recommendation for the patient. Please check quantity, dose, instructions and duration fields are all completed and are appropriate for the patient; please also note savings shown are an estimate. The quantity may have been changed to the closest available pack size. ScriptSwitch will only populate drug, dose and quantity fields following acceptance of a Recommendation. It is at the discretion of the health care professional to complete any and all other fields as appropriate. The aforementioned is subject to the terms of the [Full Disclaimer](#)

In respect of the ScriptSwitch Safety Alerts (the "Alerts"), the health care professional is solely responsible for verifying the appropriateness of the Alert for the patient. Optum Health Solutions (UK) Limited ("OHS") does not draft the clinical rules involved in determining the content of or when Alerts appear or do not appear, in general or for any particular patient. Further, OHS does not warrant or guarantee the clinical appropriateness or safety, completeness, correctness, accuracy, or timeliness of the appearance or lack thereof of any of the Alerts in general or for any particular patient. Without limiting the generality of the foregoing, OHS advises the health care professional that Alerts do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug allergies; in all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug allergies. The aforementioned is subject to the terms of the [Full Disclaimer](#)


The Safety Alert pop-up shows the following information

- **Patient Details** – processed on the desktop only
- **Safety Alert Level and Type** – Red: Admissions Avoidance, Amber: Monitoring
- **Details of the Alert** – explanation of the alert – see appendix A
- **Review Status:**
 - ! requires action
 - ✓ review action completed
- **Review Reason:** dropdown list of potential actions to be taken by user
- **Action buttons:** Hide Alert, Cancel, Hide and Close, Save and Close

Actioning a Safety Alert

The new Safety Alert allows the practice users to take relevant actions to address the Safety Alert as follows:

- Close the Alert
- Update the Review Reason and Save the Alerts for future action and reviews
- Update the Review Reason and Hide the Alert for 12 months
- Close the Alert

To ignore the Alert, select the  button or click the **X** in the top right-hand corner of the pop-up. This will clear the alert for the current session. The alert will be presented again the next time the patient record is accessed. Cancelling will not save any recorded alert reasons.


Update Review Reasons and Save & Close Alerts

Each alert can be reviewed individually, the review reason selected and then the pop-up saved for future consultations.

To update the Review Reason click the dropdown and select the most appropriate action from the available list.

| Level | Type | Details | Review Status | Review Reason | |
|-------|------------|--|---------------|-----------------|------------|
| AMBER | Monitoring | On methotrexate without recent FBC Patients receiving methotrexate for at least three months who have not had a recorded full blood count (FBC) or liver function test (LFT) within the previous three months | ! | -Review Action- | Hide Alert |
| AMBER | Monitoring | On lithium without recent lithium test Patients receiving lithium for at least three months who have not had a recorded check of their lithium concentrations in the previous three months | ! | -Review Action- | Hide Alert |
| AMBER | Monitoring | On amiodarone without recent TFT Patients receiving amiodarone for at least six months who have not had a thyroid function test (TFT) within the previous six months | ! | -Review Action- | Hide Alert |

Once a **review action** is selected the review status is marked with a **tick** indicating the alert review is completed.

| Review Status | Review Reason |
|---|-----------------------|
|  | Schedule consultation |

- When the alert reasons have been recorded click

Save and Close

Update Review Reasons and Hide & Close Alerts

- Each alert can be reviewed individually, the review reason selected and then the alert hidden for 12 months.
- To update the **Review Reason**, click the dropdown and select the most appropriate action from the available list. When all alerts have reasons set, click **Hide All and Close** button.

| | | | | | |
|--|-----------------------------|--|---|-------------------------|------------|
| RED | Admissions Avoidance | Age 65+, on oral NSAID without gastroprotection Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient aged ≥65 years | ✓ | Schedule consultation ▼ | Hide Alert |
| <div> Cancel Hide All and Close Save and Close </div> | | | | | |

The following warning message will display:

ScriptSwitch Prescribing Safety Alerts

Hiding an alert will remove the alert from the ScriptSwitch Safety Alerts pop up for the next 12 months.

Back
Continue

The user can choose to go **Back** and make changes or click **Continue** to confirm the action. If **Continue** is selected, the Safety Alert will no longer be displayed.

If **Hide All and Close** is selected and one or more of the alerts on the pop-up **does not** have a **review action**, a warning message is presented advising selection of a review reason for any alerts that do not have one.

ScriptSwitch Prescribing Safety Alerts

One or more of the alerts you are trying to hide does not have a review reason, please go 'back' and select a review reason before hiding the alert.


Back

Note:

If **Hide All and Close** is selected the review action will be saved for inclusion in the review action reports, but the alert **will not** be presented when the patient record is opened again.

Hiding a Single Alert

A single Safety Alert can be hidden by clicking the **Hide Alert** button next to the review reason option. This will hide this alert from future reviews for 12 months. This can only be achieved once the review reason is completed.

| Review Status | Review Reason |
|---|--|
|  | <div>Schedule consultation ▾</div> <div>Hide Alert</div> |

- **Hide Alert with review action selected:** a warning message advising that the alert will be removed for the next **12 months**.

ScriptSwitch Prescribing Safety Alerts

Hiding an alert will remove the alert from the ScriptSwitch Safety Alerts pop up for the next 12 months.

Back

Continue

- **Back** takes the user back and won't hide the alert
- **Continue** confirms the Hide Alert action.
- If there is only a single alert displayed for a patient, and **Continue** is selected, the safety alert will be hidden immediately, and the window closed with no further action to be taken.
- If there are multiple alerts on the pop-up, the user can continue with the review actions for other alerts or Save and Close, to close the pop-up window.

Targeted Safety Alerts on the Prescribing Pop Up

In version 7.0 of ScriptSwitch® Prescribing, patient specific safety information will now prevent risk at the **point of prescribing** by supporting the prescribing workflow, to identify patients who, through the addition of a new medication will ‘trigger’ a clinical rule using PINCER and NHS Medicines Safety Indicators. This new and important addition to ScriptSwitch® Prescribing supports **Getting it Right First Time**, the national programme designed to improve the treatment and care of patients.

The new Targeted Safety Alert on the prescribing pop-up will prevent risk at the point of prescribing by interacting with the prescribing workflow to identify patients who through the addition of a new medication will ‘trigger’ a clinical rule, using PINCER Indicators and information from the patient record.

For example:

If the patient is over 65 and isn’t receiving an NSAID or an ulcer healing drug, when the patient record is opened a Safety Alert will **not** present.

But, if this patient is then prescribed an NSAID, the prescriber will be presented with a **Safety Alert** identifying the risk and prompting the prescriber to take preventative action. In this instance, the PINCER rule A - ‘Age 65+, on oral NSAID without gastroprotection’ – would be presented.

The screenshot displays the 'ScriptSwitch Prescribing Decision Support' interface. At the top, it shows the original prescription: 'Original Naproxen 500mg gastro-resistant tablets (56 tablet) 1 TABLET TWICE DAILY Est. Cost : £5.00'. Below this is a 'Continue with Original >' button. A red box highlights a 'Safety Alert' section, which contains the text: 'Age 65+, on oral NSAID without gastroprotection Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient aged ≥65 years'. To the right of the red box, a blue callout box with an arrow points to it, containing the text: 'Safety related message on the pop-up based on current prescribing'. At the bottom of the interface, there are '< Back' and 'Feedback' buttons, and the Optum logo. A disclaimer at the very bottom states: 'The health care professional is solely responsible for verifying the appropriateness of the Recommendation for the patient. Please check quantity, dose, instructions and duration fields are all completed and are appropriate for the patient; please also note savings shown are an estimate. The quantity may have been changed to the closest available pack size. ScriptSwitch will only populate drug, dose and quantity fields following acceptance of a recommendation. It is at the discretion of the health care professional to complete any and all other fields as appropriate. Further, without limiting the generality of the foregoing, Optum Health Solutions (UK) advises the health care professional that Recommendations do not incorporate or otherwise take into account (in any way, shape or form – directly or indirectly) any aspects of the applicable patient electronic medical record relating (directly or indirectly) to drug (or other) allergies; in all cases the health care professional is solely responsible for the identification of (and any implication of) any and all drug (and other) allergies. The aforementioned is subject to the terms of the full Disclaimer.'

Safety Alert Message

If there was a switch recommendation for the original product in the profile, the following screen will display, indicating the recommended switch and highlighting the Safety Alert

Prescriber Experience

The patient record is checked at the point of opening to identify any existing patient risks, the information from that patient file is then stored in encrypted format whilst the patient record is opened. When a product is then prescribed, the details of that product are then considered against the patient details that were obtained when the patient record was opened to see if this newly triggers a risk.

Any information, other than the product being prescribed will not being considered within the risk analysis until the patient record is opened again.

Note: This service will be activated with the Safety Alerts feature, following instructions to Optum from your Medicines Optimisation teams

Data Processing

When the patient record is opened, Optum will retrieve the patient record via the Clinical System's standard APIs (Application Programming Interfaces).

Dependent on the patient's data sharing permissions, the clinical systems make data about the patient, and their medical record available via the APIs.

Using the Optum Client Manager application, installed on the prescriber machine, the ScriptSwitch Prescribing software will process the data available in the standard APIs and use information relating to the patient age, medication history, observations, and test results, for analysis within the above rules.

ScriptSwitch Prescribing software will use the patient's name, date of birth, NHS number and clinical system patient ID, available from the standard APIs, for the purpose of presenting this on the Safety Alert to ensure the alerts presented relate to the patient being viewed

The patient's data **does not** leave the prescribers machine, and is held in an encrypted format, on the prescriber's machine, **only** for the period that the patient record is open.

Optum employees have no access to the patient data.

Prior to activating this module Optum will have supported your Medicines Optimisation team in producing data privacy impact assessments and the contract contains a detailed data processing agreement, clearly defining the data processing responsibilities. For any further queries relating to data governance, please contact our customer services team in the first instance.

INPS VISION & ScriptSwitch Prescribing

Trigger Points

ScriptSwitch Prescribing will trigger for approved users at the following points if a recommendation is available in the profile:

- Acute therapy Add Window
- Repeat Master Add Window
- Acute Therapy Update window
- Repeat Master Update window
- Reauthorised Repeat Master Add Window

What is Patient Record Integration (PRI)?

ScriptSwitch Prescribing™ will now integrate with INPS Vision to obtain patient demographic information.

ScriptSwitch Prescribing compares patient demographic data with newly available drug age and gender prescribing information, with the aim of reducing fatigue by suppressing inappropriate recommendations. Fewer switch recommendations and minimal workflow disruption will allow the clinician to focus on the consultation.

PRI introduces three distinct differences in the way ScriptSwitch Prescribing will be displayed to the clinician.

- **Age and Gender:** the suppression of recommendations based on demographic information and the information available from the BNF and BNFC
- **Withholding:** the suppression of recommendations that have been rejected twice for the same patient, by the same clinician in a 12-month period. The recommendation will be withheld for a further 12 months following the second rejection.
- **Safety Alerts:** The ScriptSwitch Safety Alerts pop-up supports prescribers to efficiently manage patient risk and reduce the likelihood of a medication related hospital admission.

ScriptSwitch Prescribing Installation


To activate the site for ScriptSwitch Prescribing the following steps take place:

- Preparation of the INPS Vision database by INPS
- Installation of ScriptSwitch Prescribing software on practice PCs (not AEROS practices)
- Activation of the ScriptSwitch Prescribing software for prescribers
- Deactivation of non-clinical users
- Activation of the site with INPS Vision


User Activation

ScriptSwitch is automatically available for any Vision User who has prescribing rights within the clinical system. The ScriptSwitch rights can then be activated or deactivated by user through settings in the Vision Security Module. To change the ScriptSwitch rights take the following steps:

1. Log onto INPS Vision



2. From the main Vision screen go to the **Modules** menu and select **Control Panel**
3. From the security window, locate and right click on the user that requires ScriptSwitch to be enabled.



4. Select the user and right mouse click to access **Edit User**

5. You will see an **Enable ScriptSwitch** checkbox,

To provide the user with access – tick the box

To disable the user, remove the tick from the checkbox.

6. If the user is currently logged into Vision, changes to ScriptSwitch will take effect next time the user logs in.

NB: All new users should be checked to ensure only clinical users have ScriptSwitch rights and non-clinicians de-activated.

Frequently Asked Questions

When does the advice present itself on the screen?

Only when a prescription has been entered or re-authorised on a compatible clinical system and where a match exists with the underlying Recommendation Profile (the locally configured database of advice). The match is dependent upon the following criteria: drug name, drug strength, drug formulation, dosage, and prescription type (new acute, new repeat, repeat re-authorisation). Recommendations will also be limited by patient age and gender if PRI has been activated.

How often might a prescribing recommendation appear?

There is a direct correlation between the contents of the local Recommendation Profile (number of items), the drugs prescribed in the locality, and the frequency with which prescribing recommendations might appear. Based on data from existing ScriptSwitch Prescribing users, prescribers can expect to see a recommendation for between 5% and 10% of prescriptions entered or re-authorised.

How often are recommendations accepted?

On average, from analysis of existing ScriptSwitch Prescribing users, between 30% to 40% of recommendations are accepted when initially offered. However, for some categories of user (e.g., locums) acceptances run at up to 70%. The acceptance rates correlate with the quality of reason associated with each recommendation (inc. evidence source quoted), but also with the frequency of practice contact and reviews undertaken by the local prescribing support team.

How much time does ScriptSwitch Prescribing add to the consultation process?

ScriptSwitch Prescribing has been designed from its inception to be quick and simple to use. Just ONE* click is needed to either accept, decline, or acknowledge the presented advice from a single window interface.

What happens after the advice is either ACCEPTED or DECLINED?

If the advice is **declined**, the advice-box instantly disappears, and the host clinical system will continue with whatever it was “expecting” to do at the point that ScriptSwitch Prescribing interacted. If the advice is **accepted**, the advice-box instantly disappears, and the drug details entered moments earlier are automatically replaced with the advised suggestion. The host software will then behave as if these were the original drug details entered. Whatever the choice is made, a log is automatically recorded of the “offer of the advice” and the decision made. This offers an automated feedback mechanism to allow an assessment of the effectiveness and relevance of the advice and enabling the local prescribing support team to refine the Recommendation Profile.

What's in the Recommendation Profile?

Drug-specific advice, either an alternative suggestion or an “information-only” message chosen initially by the **local prescribing** support team and then refined in the light of feedback.

The advice is configured by drug name, drug strength, drug formulation, dosage, patient demographic data, and prescription type.

**This may vary if the prescriber decides to write feedback from the ScriptSwitch Prescribing.*

On-going Support

How to contact Customer Services:

Telephone: 024 7621 4700

Email: support@scriptswitch.com

Hours: Monday – Friday 8am – 6pm

Technical Issues

The ScriptSwitch Prescribing product has been available for several years and is a stable product. Our Customer Services team regularly monitors the activity from each site. Specifically, we are monitoring:

- That the site is connecting to our server daily
- That the script data is being sent to our servers daily
- That the average number of prescriptions per day remains within 80% of the calculated average for the period of use of ScriptSwitch Prescribing.
- That software updates when available have been applied via our remote patching system

Most of the support issues experienced come about because of the following situations.

- **New PCs** – The ScriptSwitch Prescribing software is held on the PCs within the practice. If PCs are replaced, the ScriptSwitch Prescribing software will have to be re-installed. This can be achieved easily from a call to our customer services team
- **User Activation** - With INPS Vision users can be activated and deactivated from Control Module and editing the user within Vision. It is the practice's responsibility to ensure that only appropriate trained staff have access to ScriptSwitch Prescribing. The additional patient record integration features will need to be activated by the user when the tick box presents on their PC
- **Clinical System Migration** – call the team so we can reactivate on your new clinical system
- **Merged Practices** - call the team so we can reactivate on your new clinical system



Software Updates

From time to time, we will notify you of a software update.

These are applied by a remote software update process which is monitored by our customer services team.

Updates will be collected by each PC and will be installed to the PC during the next reboot (i.e., when the machine is logged off and then back on next morning)

On the rare occasions that the update fails we will contact you to arrange for rectification.

We always provide release notes, and these should be circulated to your prescribers.

On occasions new features and functionality will be installed and additional training webinars will be available for practice users.